Company
We Serve
Conditions Treated
Bleeding Disorders
At Soleo Health, our experienced specialty pharmacy and infusion teams provide personalized support for patients receiving hemophilia therapies, helping coordinate treatment, navigate insurance requirements, and improve long-term outcomes.
Hemophilia is a rare, inherited bleeding disorder that prevents blood from clotting properly. People with hemophilia have low levels or a deficiency of specific clotting factors, proteins that work together to stop bleeding after an injury.
Without enough clotting factor, bleeding can last longer than normal and may occur spontaneously, particularly in joints, muscles, and internal tissues. Over time, repeated bleeding episodes can lead to chronic pain, joint damage, and reduced mobility.
Advances in treatment have transformed hemophilia care, allowing many individuals to live active, healthy lives through preventive therapies, factor replacement treatments, and comprehensive care management.
Hemophilia occurs when the body lacks sufficient clotting factors needed to form blood clots. The most common types include:
Hemophilia A accounts for approximately 80% of all hemophilia cases, caused by a deficiency in clotting factor VIII (factor 8). It affects about 1 in 5,000 male births.
Hemophilia B results from a deficiency of clotting Factor IX and is sometimes referred to as Christmas disease.
Unlike inherited forms, acquired hemophilia develops when the immune system mistakenly attacks clotting factors. This condition is rare but can cause serious bleeding complications.
Diagnosis typically involves:
Family and Medical History Review of bleeding episodes and family history of bleeding disorders.
Blood Testing Laboratory testing may measure:
Genetic testing can help confirm a diagnosis and identify specific mutations associated with hemophilia.
Hemophilia is generally classified based on clotting factor activity levels.
Mild Hemophilia Patients may experience bleeding primarily after surgery, dental work, or significant injury.
Moderate Hemophilia Bleeding episodes occur more frequently and may result from minor injuries.
Severe Hemophilia Spontaneous bleeding into joints and muscles can occur without obvious injury.
Symptoms vary depending on the severity of the condition and the amount of clotting factor present.
Common symptoms include:
Prolonged Bleeding – Bleeding that continues longer than expected after:
Joint Bleeding Repeated bleeding into joints can cause:
Commonly affected joints include:
Internal Bleeding In severe cases, bleeding may occur in:
Benjamin was told he might not live past 30. Today, he’s redefining what life with hemophilia looks like.
From being known as “the hemophiliac” to simply Benjamin, his journey is one of resilience, innovation, and the power of the right care team. Living hours from his treatment center in Alaska, access and support could have been barriers, but instead, they became breakthroughs.
Great care isn’t just about treatment; it’s about relationships, trust, and knowing you can reach someone who truly understands when you need it most.
It’s having people you can call when you have questions, when something doesn’t feel right, or even when you just need to talk to someone who understands.
Treatment involves replacing the missing clotting factor through regular infusions of clotting factor concentrates. People with hemophilia often learn to self-administer these treatments at home. With proper treatment, people with hemophilia can lead relatively normal lives, though they need to take precautions to avoid injuries and work closely with specialized medical teams.
Hemophilia is a rare bleeding disorder that needs specialized care, consistent therapy, and reliable support. At Soleo Health, we’re committed to helping patients manage hemophilia by providing access to specialty medications, infusion therapies, and experienced care teams.
Factor replacement therapy replaces missing clotting factors through intravenous infusion. Common therapies include:
Hemophilia treatments that help prevent bleeds without directly replacing factor VIII or factor IX. Most are given subcutaneously and work by either mimicking clotting activity or “rebalancing” the clotting system.
Unlike traditional factor replacement, these therapies are not factor VIII or factor IX products. They are designed to reduce bleeding by promoting clot formation via alternative pathways.
Alhemo® (concizumab-mtci) — Approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with:
Hemlibra® (emicizumab-kxwh) — Approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A, also known as congenital factor VIII deficiency.
Hympavzi® (marstacimab-hncq) — Approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 6 years of age and older with:
Qfitlia® (fitusiran) — Approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with:
Hemophilia treatment often requires ongoing therapy management, specialized medication handling, and coordinated care among multiple healthcare providers.
Soleo Health provides comprehensive support services for individuals living with hemophilia.
Our patient advocate help patients navigate prior authorizations, insurance approvals, financial assistance programs, and manufacturer support resources
Our Patient Assistance team researches copay support programs and charitable foundations that may reduce out-of-pocket treatment costs
We work closely with Hematologists, Specialty treatment centers, Caregivers and Health plans to ensure seamless care delivery.
Patients and providers can reach our care teams any time, day or night, for support with infusions or urgent questions
We have pharmacy licensure in all 50 states and national nursing coverage. We can care for you no matter where you live.
Every patient has a dedicated patient advocate who helps with insurance, education, and ongoing support.
Inhibitors are antibodies that the immune system develops against clotting factor treatments, making them less effective or completely ineffective.
They’re one of the most serious complications of hemophilia treatment.
When a person with hemophilia receives factor VIII or IX concentrates, their immune system may mistakenly recognize these proteins as “foreign” and produce antibodies to neutralize them.
These antibodies are called inhibitors because they inhibit or block the function of the clotting factor.
The length of a hemophilia infusion can vary based on the medication and dose, but most factor infusions take about 5-15 minutes.
Your care team will walk you through the process and ensure you feel comfortable administering treatment at home or receiving it at one of our infusion centers.
Currently, there is no cure for inherited hemophilia, although gene therapy has shown promising results for some patients. Most individuals manage the condition through long-term treatment and monitoring.
Many hemophilia therapies can be administered at home under the guidance of healthcare providers, depending on the patient’s treatment plan.
The frequency depends on the treatment plan. Some patients use hemophilia infusions on a regular schedule to prevent bleeds (called prophylactic treatment), while others only infuse when a bleed happens (on-demand treatment). Providers work closely with patients to determine the best schedule.
At-home care usually includes the clotting factor medication, syringes or infusion sets, and sterile supplies. Soleo Health makes it simple by delivering customized medical kits with everything needed for hemophilia treatment injections or infusions.
Yes. Many patients travel with their factor products, and Soleo Health helps coordinate medication delivery to different locations when needed. Our national coverage supports patients wherever life takes them.
No, factor X deficiency is not considered a form of hemophilia. While it’s also a bleeding disorder caused by a clotting factor X deficiency, hemophilia specifically refers to deficiencies in factors VIII, IX, or XI.
Factor X deficiency is classified as a separate rare bleeding disorder. Here’s the distinction:
Hemophilia:
Factor X deficiency is much rarer than hemophilia A or B, affecting roughly 1 in 500,000 to 1 in 1,000,000 people. Unlike hemophilia A and B, which are X-linked and primarily affect males, factor X deficiency follows an autosomal recessive inheritance pattern, meaning it affects males and females equally.
The symptoms can be similar to hemophilia – excessive bleeding, easy bruising, and prolonged bleeding after injuries or surgeries – but the underlying cause (which specific clotting factor is deficient) and inheritance pattern are different.
While factor X deficiency is a serious bleeding disorder that requires medical management similar to hemophilia, it’s classified as a separate condition rather than a type of hemophilia.
Going above and beyond filling prescriptions, Soleo Health is a complex specialty pharmacy providing a personalized patient experience and access to specialty medications and infusion therapies for patients with bleeding disorders.
Bleeding Disorder Therapies
AUTOPLEX T®
HYATE-C®
STIMATE®
<span data-mce-type="bookmark" style="display: inline-block; width: 0px; overflow: hidden; line-height: 0;" class="mce_SELRES_start"></span>
See the Transcript
Visit Site